Managing toxicities of concurrent chemotherapy and radiation (CRT), assessing the status of disease during treatment, and timing the initiation of consolidation immunotherapy are some of the challenges facing oncologists managing stage III unresectable non-small cell lung cancer patients in both metro and regional settings. In a webinar chaired by Associate Professor Nick Pavlakis (view webinar ...
Achieving optimal management of Stage III unresectable NSCLC in metro and regional settings: experts
2 Dec 2020
Sponsored by AstraZeneca Pty Ltd